Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TAF1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TAF1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TAF1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TAF1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190336417 | Endometrium | EEC | positive regulation of cellular protein catabolic process | 42/2168 | 155/18723 | 8.59e-08 | 4.33e-06 | 42 |
GO:004217716 | Endometrium | EEC | negative regulation of protein catabolic process | 35/2168 | 121/18723 | 1.79e-07 | 8.20e-06 | 35 |
GO:005109917 | Endometrium | EEC | positive regulation of binding | 44/2168 | 173/18723 | 3.08e-07 | 1.27e-05 | 44 |
GO:190336314 | Endometrium | EEC | negative regulation of cellular protein catabolic process | 25/2168 | 75/18723 | 5.43e-07 | 2.04e-05 | 25 |
GO:004586117 | Endometrium | EEC | negative regulation of proteolysis | 72/2168 | 351/18723 | 8.46e-07 | 2.98e-05 | 72 |
GO:004339315 | Endometrium | EEC | regulation of protein binding | 46/2168 | 196/18723 | 1.94e-06 | 5.80e-05 | 46 |
GO:200005916 | Endometrium | EEC | negative regulation of ubiquitin-dependent protein catabolic process | 18/2168 | 48/18723 | 3.08e-06 | 8.48e-05 | 18 |
GO:190179617 | Endometrium | EEC | regulation of signal transduction by p53 class mediator | 27/2168 | 93/18723 | 4.07e-06 | 1.06e-04 | 27 |
GO:190305114 | Endometrium | EEC | negative regulation of proteolysis involved in cellular protein catabolic process | 21/2168 | 64/18723 | 5.73e-06 | 1.40e-04 | 21 |
GO:190305215 | Endometrium | EEC | positive regulation of proteolysis involved in cellular protein catabolic process | 34/2168 | 133/18723 | 5.80e-06 | 1.41e-04 | 34 |
GO:007233117 | Endometrium | EEC | signal transduction by p53 class mediator | 39/2168 | 163/18723 | 7.00e-06 | 1.63e-04 | 39 |
GO:003133017 | Endometrium | EEC | negative regulation of cellular catabolic process | 55/2168 | 262/18723 | 7.93e-06 | 1.80e-04 | 55 |
GO:005110117 | Endometrium | EEC | regulation of DNA binding | 31/2168 | 118/18723 | 8.11e-06 | 1.81e-04 | 31 |
GO:200006017 | Endometrium | EEC | positive regulation of ubiquitin-dependent protein catabolic process | 29/2168 | 107/18723 | 8.16e-06 | 1.82e-04 | 29 |
GO:003243616 | Endometrium | EEC | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 25/2168 | 90/18723 | 2.12e-05 | 3.83e-04 | 25 |
GO:003209213 | Endometrium | EEC | positive regulation of protein binding | 24/2168 | 85/18723 | 2.29e-05 | 4.08e-04 | 24 |
GO:190180016 | Endometrium | EEC | positive regulation of proteasomal protein catabolic process | 29/2168 | 114/18723 | 3.02e-05 | 5.26e-04 | 29 |
GO:000989516 | Endometrium | EEC | negative regulation of catabolic process | 61/2168 | 320/18723 | 5.76e-05 | 8.97e-04 | 61 |
GO:003090113 | Endometrium | EEC | midbrain development | 23/2168 | 90/18723 | 1.80e-04 | 2.21e-03 | 23 |
GO:005110016 | Endometrium | EEC | negative regulation of binding | 35/2168 | 162/18723 | 1.85e-04 | 2.26e-03 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TAF1 | SNV | Missense_Mutation | novel | c.3409N>A | p.Gln1137Lys | p.Q1137K | P21675 | protein_coding | deleterious(0.04) | probably_damaging(0.991) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
TAF1 | SNV | Missense_Mutation | novel | c.4912G>A | p.Asp1638Asn | p.D1638N | P21675 | protein_coding | tolerated(1) | benign(0.092) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.5638N>A | p.Glu1880Lys | p.E1880K | P21675 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TAF1 | SNV | Missense_Mutation | novel | c.85N>A | p.Asp29Asn | p.D29N | P21675 | protein_coding | tolerated_low_confidence(0.1) | benign(0.124) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TAF1 | SNV | Missense_Mutation | novel | c.4675N>T | p.Pro1559Ser | p.P1559S | P21675 | protein_coding | deleterious(0.01) | possibly_damaging(0.752) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
TAF1 | SNV | Missense_Mutation | | c.1679G>T | p.Arg560Leu | p.R560L | P21675 | protein_coding | deleterious(0) | benign(0.44) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.4174C>T | p.His1392Tyr | p.H1392Y | P21675 | protein_coding | tolerated(0.17) | benign(0.021) | TCGA-AN-A0AS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TAF1 | SNV | Missense_Mutation | | c.2195N>G | p.Asp732Gly | p.D732G | P21675 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TAF1 | SNV | Missense_Mutation | rs760338471 | c.2698A>G | p.Met900Val | p.M900V | P21675 | protein_coding | deleterious(0.03) | benign(0.049) | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
TAF1 | SNV | Missense_Mutation | | c.1816G>A | p.Gly606Arg | p.G606R | P21675 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A1AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | SD |